Imakethe yomhlaba wonke yokulahlekelwa isisindo iyaqhubeka ikhula futhi ithuthuke, ngesidingo esikhulayo sezixazululo ezisebenzayo neziphephile zokulahlekelwa isisindo.Omunye wabadlali abakhulu kule makethe isithako sokulahlekelwa isisindo semaglutide (CAS 910463-68-2).I-Semaglutide i-glucagon-like peptide-1 (GLP-1) receptor agonist esetshenziselwa ukwelapha uhlobo lwesifo sikashukela sohlobo lwe-2 futhi isanda kuthola ukunakwa ngokusetshenziswa kwayo okungenzeka ekulawuleni isisindo.
I-Semaglutide isebenza ngokulingisa imiphumela ye-GLP-1, i-hormone eyenzeka ngokwemvelo emzimbeni esiza ukulawula amazinga kashukela egazini.Kuye kwaboniswa ukunciphisa isifiso sokudla nokudla, okuholela ekulahlekelweni kwesisindo kubantu abanokukhuluphala ngokweqile.Lokhu kwenza i-semaglutide ibe yindlela ekhangayo kulabo abafuna ukufeza izinhloso zabo zokulahlekelwa isisindo.
Imakethe yezithako zokulahlekelwa isisindo emhlabeni jikelele, okubandakanya i-semaglutide, kulindeleke ukuthi ifakaze ukukhula okuphawulekayo eminyakeni ezayo.Izinto ezinjengokwanda kokudlanga kokukhuluphala ngokweqile, ukuqwashisa okukhulayo ngezingozi zezempilo ezihlobene nokukhuluphala, kanye nesidingo esikhulayo sezixazululo ezisebenzayo zokulahlekelwa isisindo kuqhuba ukwanda kwemakethe.
Izinkampani eziningana zemithi zibambe iqhaza ngenkuthalo ekuthuthukiseni nasekuthengiseni i-semaglutide yokuphatha isisindo.U-Novo Nordisk, umholi wembulunga yonke ekwelashweni kwesifo sikashukela, usungule umjovo wamasonto onke we-semaglutide oqondene nokuncipha kwesisindo.Le nkampani yenza izivivinyo eziningi zomtholampilo ezibonisa ukuphepha nokusebenza kwe-semaglutide ekukhuthazeni ukulahlekelwa isisindo, ngemiphumela ekhuthazayo.
Ngo-2021, i-US Food and Drug Administration (FDA) yagunyaza i-semaglutide yokuphathwa kwesisindo sesikhathi eside kubantu abadala abakhuluphele noma abakhuluphele kakhulu okungenani abane-comorbidity eyodwa ehlobene nesisindo.Lokhu kuphawula ingqophamlando ebalulekile emakethe yesithako sokuncipha kwesisindo somhlaba njengoba kungokokuqala ukuthi i-GLP-1 receptor agonist igunyazwe ngokukhethekile ukulawula isisindo.
Ngaphezu kwe-United States, amanye amazwe ayaqaphela amandla e-semaglutide okubhekana nobhubhane lokukhuluphala.I-European Commission inikeze ukugunyazwa kokumaketha ku-semaglutide yokwelapha ukukhuluphala, nezimvume ezengeziwe ezilindelwe ezimakethe zamazwe ngamazwe ezihlukahlukene.Ukuqashelwa okusabalele kanye nokwamukelwa kwe-semaglutide yokuncipha kwesisindo kuqhubezela nokuqinisa isikhundla sayo njengomdlali obalulekile emakethe yokulahlekelwa isisindo emhlabeni jikelele.
Njengoba imakethe yomhlaba wonke yezithako zokulahlekelwa isisindo iqhubeka nokukhula, kubalulekile ukuthi izinkampani zemithi zibeke phambili ukuthuthukiswa kwezixazululo eziphephile nezisebenzayo.I-Semaglutide ifakazele ikhono lokukhuthaza ukwehla kwesisindo nokuthuthukisa impilo ye-metabolic, iyenze ibekwe kahle ukuze ihlangabezane nesidingo esikhulayo semikhiqizo yokuphatha isisindo.Ngokuqhubeka kwemizamo yocwaningo nentuthuko, i-semaglutide kulindeleke ukuthi ibambe iqhaza elibalulekile ekubhekaneni nobhubhane lokukhuluphala emhlabeni wonke kanye nokusiza abantu ukuthi bafinyelele imigomo yabo yokulahlekelwa isisindo.
Isikhathi sokuthumela: Dec-07-2023